69results about How to "Reduced burst effect" patented technology

A method of coating implantable open lattice metallic stent prosthesis is disclosed which includes sequentially applying a plurality of relatively thin outer layers of a coating composition comprising a solvent mixture of uncured polymeric silicone material and crosslinker and finely divided biologically active species, possibly of controlled average particle size, to form a coating on each stent surface. The coatings are cured in situ and the coated, cured prosthesis are sterilized in a step that includes preferred pretreatment with argon gas plasma and exposure to gamma radiation electron beam, ethylene oxide, steam.

A coating and method for a coating an implantable device or prostheses are disclosed. The coating includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed herein. The coating further includes a topcoat which covers less than the entire surface of the undercoat and wherein the topcoat comprises a polymeric material substantially free of pores and porosigens. The polymeric material of the topcoat can be a biostable, biocompatible material which provides long term non-thrombogenicity to the device portion during and after release of the biologically active material.

A system, method and computer program product is provided for mitigating the effects of burst noise on packets transmitted in a communications system. A transmitting device applies an outer code, which may include, for example, a block code, an exclusive OR (XOR) code, or a repetition code, to one or more packets prior to adaptation of the packets for transmission over the physical (PHY) layer of the communications system, wherein the PHY layer adaptation may include FEC encoding of individual packets. The outer coded packets are then separately transmitted over a channel of the communications system. A receiving device receives the outer coded packets, performs PHY level demodulation and optional FEC decoding of the packets, and then applies outer code decoding to the out6r coded packets in order to restore packets that were erased during transmission due to burst noise or other impairments on the channel.

The invention provides a small molecule drug in-situ phase-change gel sustained release agent with phospholipid and span as matrices and a preparation method thereof. By the adoption of the simple method, the phospholipid and span sustained release agent is prepared from phospholipid, span, active pharmaceutical ingredients and ethanol solutions of different concentrations, and has the advantages that the biocompatibility is good, the adverse reaction is low, the burst-release and inhibition capability is high, and the releasing time is prolonged; the sustained release agent is suitable for various drug administration modes such as subcutaneous injection and external drug administration, the amount of carried drugs can be adjusted conveniently according to the clinical medication dosage of the drugs, and the sustained release agent and the preparation method thereof have broad application prospects.

The invention relates to aripiprazole sustained-release microspheres and a preparation method thereof. The sustained-release microspheres include aripiprazole and a bio-degradable pharmaceutical high-molecular material PLGA, wherein the ratio of lactic acid to hydroxyacetic acid in the PLGA is 75:50-25:50. The PLGA is 25000-35000 Dolton in molecular weight. The addition weight ratio of the aripiprazole to the PLGA is 1:1-20. The aripiprazole accounts for 3.01-21.09% of total weight of the microsphere. The aripiprazole sustained-release microspheres have high drug embedding rate, is high in drug loading capacity, is smooth and round in surface and can release more than 90% of the drug in 30 days.

Embodiments of the present invention disclose systems and methods for providing an enhanced data link using overlaid modulation. Through embodiments of the present invention, existing ATC (or other) modulated signals using existing standard frequencies may be utilized to transmit (e.g., from an aircraft transponder) additional information in a manner that does not render the transmitted signal unrecognizable by legacy ATC equipment. Legacy equipment will be able to demodulate and decode information that was encoded in the transmitted signal in accordance with preexisting standard modulation formats, and updated equipment can also extract the additional information that was overlaid on transmitted signals.

The invention relates to the technical field of pharmaceutical preparation, in particular to an asiatic acid sustained-release microsphere used for injection and a preparation method thereof. A biodegradable chitosan is taken as a carrier, an asiatic acid is taken as principal agent, and the asiatic acid sustained-release microsphere used for injection is obtained by the technology of cross-linked emulsion. Due to the obtained medicament carried microspheres, the surfaces are relatively smooth; the particle diameters range from 20mum to 110mum; and the medicament loading rate of the microspheres ranges from 4.8% to 15.6%. The asiatic acid microsphere has the characteristics that the burst effect is modest (the burst size on the first day is smaller than 15%); the release rate is stable; the sustained release time is long (4-10 weeks); and the asiatic acid microsphere is biodegradable. The implantation and the removal by operation before and after the medicament is used are avoided.

A system, method and computer program product is provided for mitigating the effects of burst noise on packets transmitted in a communications system. A transmitting device applies an outer code, which may include, for example, a block code, an exclusive OR (XOR) code, or a repetition code, to one or more packets prior to adaptation of the packets for transmission over the physical (PHY) layer of the communications system, wherein the PHY layer adaptation may include FEC encoding of individual packets. The outer coded packets are then separately transmitted over a channel of the communications system. A receiving device receives the outer coded packets, performs PHY level demodulation and optional FEC decoding of the packets, and then applies outer code decoding to the outer coded packets in order to restore packets that were erased during transmission due to burst noise or other impairments on the channel.

The invention relates to an iloperidone sustained release microsphere and a preparation method thereof. The sustained release microsphere mainly comprises iloperidone and a biodegradable pharmaceutical polymer material PLGA (poly lactic-co-glycolic acid), wherein the molar ratio of lactic acid of PLGA to glycolic acid is (75-50):(25-50), the dosing weight ratio of the iloperidone to the PLGA is 1:(1-10), and the iloperidone is 3.5-15.5% of the total weight of the microsphere. According to the prepared iloperidone sustained release microsphere, the medicine encapsulation efficiency is high, the drug loading capacity is high, and the surface of the microsphere is smooth and round. The sustained release microsphere is used for curing psychosis, can prolong the action time of the medicine, reduces the dosing times, and greatly improves the obedience of patients in taking medicine.

The invention relates to a biological adhesive microsphere with a nuclear shell double-layer structure and a preparation method of the microsphere. By taking Zujin pill total alkaloids as a model medicine, taking natural high-molecular polymers such as chitosan, sodium alga acid and gelatin as carrier materials, an intelligent hydrogel medicine release system with biological adhesiveness is constructed. Due to the biological adhesive microsphere with the nuclear shell structure, detention time of the medicine in stomach is prolonged, medicine absorption is increased, and the biological availability of oral medicine for treating gastrohelcosis is improved. The biological adhesive microsphere is a reasonable and effective novel dosage form of gastrohelcosis-resisting medicine developed by using ancient prescription into a modern research method. The invention further illuminates in-vitro medicine release performance of the microsphere and in-vitro biological adhesion effect of the microsphere.

The invention relates to a long-acting cefotaxime sodium injection and a preparation method of the injection. The injection comprises a biodegradable polymer material, wherein the biodegradable polymer material comprises an injectable hydrogel. The preparation method comprises the following steps: mixing the medicines and N-chitosan succinate solution at a certain temperature and stirring rate, and mixing the mixture with carboxymethyl chitosan solution; adding oxidized chondroitin sulfate solution and glutaraldehyde solution in a certain time while stirring, injecting the solution into a circular mold with the bottom diameter of 10mm after stirring, forming drug-loading hydrogel, and performing vacuum drying to constant weight at room temperature.

The invention provides a preparation method of acetic acid goserelin microspheres. The preparation method includes: step 1), mixing acetic acid goserelin with water to obtain a drug solution A, and mixing PLGA (polylactic-co-glycolic acid) with an organic solution to obtain a solution B; step 2), mixing the solution A with the solution B to form colostrum through ultrasound, and adding the colostrum to a PVA (polyvinyl acetate) water solution saturated by an organic mixed solution to obtain a compound emulsion through homogeneous emulsification; step 3), stirring the compound emulsion at the room temperature for one hour, increasing the temperature to 40-45 DEG C, keeping the compound emulsion for one hour, reducing the temperature to 10 DEG C, sieving the compound emulsion to collect particles and subjecting the particles to freeze-frying. The preparation method has the advantages that the problem of adverse drug reaction increase caused by high sudden release effect of the acetic acid goserelin microspheres can be solved, and the microspheres prepared by the method have quite smooth and stable blood concentration and are beneficial to long-term medication.

The invention relates to a preparation method of drug-carrying liposome. In the method, a two-step freeze-drying method is used for preparing the liposome for coating and carrying water soluble drugs, wherein a primary freeze drying process is performed in a water phase system, and a secondary freeze drying process is performed in an organic phase system. The water soluble drugs are evenly coated and carried in the liposome by the two-step freeze drying method, thus improving the envelopment rate of the drugs and reducing the initial burst release effect of the liposome for coating and carrying the water soluble drugs. The liposome prepared by the preparation method is suitable for coating various kinds of water soluble drugs and has a wide range of applicable dosage forms.

The invention provides a protein polypeptide medicine duplex microsphere and a preparation method thereof. The method comprises the following steps of S1, performing medicine loading on protein polypeptide medicine and chitosan in weak acidic solvents; obtaining a nanometer particle solution; sequentially performing film filtering and reduced pressure drying to obtain the medicine coated chitosannanometer particles; S2, under the effect of coupling agents, performing grafting reaction on the medicine coated chitosan nanometer particles and polylactic acid to obtain the protein polypeptide medicine duplex microsphere. The invention also provides an insulin duplex microsphere, which is prepared by the method. The insulin duplex microsphere has the advantages that the use is safer; the patient tolerance is better; the effect is longer; the medicine effect is more stable; the sudden release is obviously reduced.

The invention discloses a method for preparing medicine-carrying hydroxyapatite/poly glycolide-co-lactide (PLGA)/chitosan demixing microspheres. The method comprises the following steps of: dissolving isoniazide in deionized water, adding hydroxyapatite powder, stirring in a dark place, and freeze-drying to obtain powder; mixing PLGA and the powder uniformly to obtain a hydroxyapatite/PLGA commixed solution containing the isoniazide; dissolving chitosan in an acetic acid aqueous solution to obtain a chitosan solution; mixing the chitosan solution and a polyvinyl alcohol aqueous solution to obtain a chitosan/polyvinyl alcohol solution; and pouring the hydroxyapatite/PLGA commixed solution containing the isoniazide into the chitosan/polyvinyl alcohol solution, stirring under vacuum, washingby using water, and freeze-drying to obtain the medicine-carrying hydroxyapatite/PLGA/chitosan demixing microspheres. The prepared medicine-carrying composite microspheres are regular in spherical shapes, uniform in particle size distribution, high in envelop rate of medicines, long in in-vitro medicine release time and small in burst release; and a preparation process is simple, raw materials are readily available, and industrialization is easy to realize.